GlassScriptPhysician profile
Cannon Milani
NPI 1811212491
$9,136.54
in general payments reported to CMS, 2019-2025
28 companies · $3,453 in 2025
The $3,453 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $315 · 2021: $326 · 2022: $2,931 · 2023: $656 · 2024: $1,226 · 2025: $3,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,236 · Consulting Fee: $2,000 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,235.96 |
| Consulting Fee | $2,000.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $2,593.49 | 2022-2025 | Enhertu |
| Springworks Therapeutics, INC. | $2,262.11 | 2024-2025 | Ogsiveo |
| Novartis Pharmaceuticals Corporation | $1,693.54 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $410.34 | 2019-2024 | Onivyde, Somatuline Depot |
| Celgene Corporation | $349.30 | 2019-2023 | Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $254.12 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $223.07 | 2021-2025 | Calquence |
| Seagen INC. | $189.96 | 2020 | |
| Aadi Bioscience, INC. | $129.62 | 2022 | |
| Emd Serono, INC. | $112.39 | 2023-2024 | Bavencio |
| Sanofi-Aventis U.S. LLC | $99.00 | 2025 | |
| Pfizer INC. | $97.58 | 2025 | |
| Abbvie INC. | $90.65 | 2024-2025 | |
| Array Biopharma INC | $80.00 | 2025 | Mektovi, Braftovi, Tukysa |
| Gilead Sciences, INC. | $65.64 | 2025 | Trodelvy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $64.04 | 2024-2025 | Fruzaqla, Alunbrig |
| Sun Pharmaceutical Industries INC. | $54.67 | 2024 | |
| Jazz Pharmaceuticals INC. | $52.20 | 2024-2025 | |
| Eisai INC. | $49.74 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $42.88 | 2024 | Tavalisse, Rezlidhia |
| Janssen Biotech, INC. | $35.04 | 2024-2025 | Tecvayli |
| Merck Sharp & Dohme LLC | $28.53 | 2024 | Keytruda |
| Beigene USA, INC. | $27.97 | 2025 | Brukinsa |
| Pharmaessentia USA Corporation | $26.81 | 2024 | Besremi |
| Karyopharm Therapeutics INC. | $26.74 | 2024 | Xpovio |
| Incyte Corporation | $26.11 | 2024 | Jakafi |
| Blueprint Medicines Corporation | $26.00 | 2025 | Ayvakit |
| Glaxosmithkline, LLC. | $25.00 | 2024 | Jemperli, Zejula |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cannon Milani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.